DOC

EB virus latent membrane protein (LMP1) and expression of survivin in nasopharyngeal carcinoma_1419

By Ethel Evans,2014-10-30 16:07
10 views 0
EB virus latent membrane protein (LMP1) and expression of survivin in nasopharyngeal carcinoma_1419

    EB virus latent membrane protein (LMP1) and expression of survivin in nasopharyngeal carcinoma

     Abstract Objective To investigate the nasopharyngeal squamous cell carcinoma of EB virus latent membrane protein LMP1, and survivin expression and prognosis. Methods The

    immunohistochemical SP method, 83 cases of nasopharyngeal squamous cell carcinoma of the organizations LMP1 and survivin tags, analyzed the clinical stage, radiation therapy within three years after the results of relationship. The results of

    LMP1 expression and clinical stage (P> 0.05), but relapse within three years after radiotherapy (P <0.05). survivin and clinical stage, relapse within three years after radiotherapy (P <0.05). LMP1 and survivin are associated (P <0.05).

    Conclusion LMP1 and survivin in nasopharyngeal carcinoma has important prognostic value, can be used for clinical treatment of the reference index.

     Key words nasopharyngeal carcinoma LMP1; survivin immunohistochemistry

     Expressions of Epstein Barr Virus Latent Membrane Protein

    1 (LMP1) and survivin in Nasopharyngeal Carcinoma and their Clinical Significance

     Key words: Nasopharyngeal; Carcinoma; LMP1; survivin; Immunohistochemical method

     NPC (Nasopharyngeal carcinoma, NPC) is a common malignant tumor in China, particularly Guangdong and Guangxi areas of high-fat, with the gradual in-depth on the NPC study, EBV

    infection and is closely related to people's NPC has been recognized. survivin is an inhibitor of apoptosis, studies

    have shown that the degree of survivin expression in stage of disease progress and the extent of malignant tumor tissue is consistent. We used immunohistochemistry to detect NPC in

poorly differentiated squamous cell carcinoma of the most

    common pathological tissues and survivin expression of LMP1, combined with clinical stage, three years after radiotherapy for recurrence of such information as to whether the study to explore both in the NPC the role of the relationship and its significance.

     1 Materials and methods

     1.1 Materials

     83 cases of nasopharyngeal carcinoma specimens were from our hospital in January 1998 ~ January 2002 close examination of the paraffin-embedded tissues.

     1.2 Grouping

     NPC clinical stages of nasopharyngeal carcinoma according to the National Conference, Fuzhou in 1992, recommended standards [1], the 28 patients with stage ? ~ ?, ? period

    of 26 cases, ? period 29 patients were divided into three groups; by radiotherapy would be cases of relapse within three

    years whether the were divided into 48 cases without recurrence group and recurrence of group two sets of 35 cases.

     1.3 Immunohistochemical detection method

     Using peroxidase labeled streptavidin staining S P

    method. Using an antibody were purchased in the United States Santa Cruz company's products, using the work of the concentration of antibodies: mouse anti-human monoclonal

    antibody LMP1 1:80, rabbit polyclonal antibody anti-human

    survivin 1:100, SP kit purchased from Beijing Zhongshan

    Company, the entire process carried out according to kit instructions. With phosphate buffer (phosphatic buffered saline, PBS) instead of a resistance as negative control.

     1.4 criterion

     LMP1 in cancer cells cytoplasm, membrane yellow-brown

    granules, survivin in cancer cell nuclei and cytoplasm yellow-

    brown granules, the number of positive cells "of 5% positive mark.

     1.5 Statistical analysis

     Using SPSS11.5 software, χ2 test. PEMS3.0 software,

    correlation analysis. P <0.05 significant differences.

     2 Results

     2.1LMP1 and survivin in nasopharyngeal carcinoma in different clinical stages of expression groups

     (1) LMP1 in ? ~ ? stage cases, 28 cases of negative

    expression shown in Figure 1, expression shown in Figure 2, the positive rate is higher than in stage ? case group, below

    the case group stage ?. However, LMP1 in different stages of the positive rates showed no significant difference. (2)

    survivin in ? ~ ? stage cases, 28 cases of negative

    expression shown in Figure 3, positive expression shown in Figure 4, the positive rate of less than the case group stage ? and ? case group, ? ~ ? Phase The positive rate of stage ? Group, ? stage group was statistically significant positive rates, ? period, ? stage group showed no

    significant difference in positive rates in Table 1. Table 1 LMP1, survivin expression and clinical stages of NPC poorly differentiated squamous cell carcinoma of the relationship

    between the Note: LMP1 in the group stage ? ~ ? and stage ?

    positive rate of positive rate of a comparison: χ2 = 0.0593,

    P = 0.08075; ? ~ ? Phase Group stage ? positive rate and

    positive rate of a comparison: χ2 = 0.0128, P = 0.9101; ?

    period The positive rate of stage ? a comparison group: χ2 =

    0.1271, P = 0.7215. survivin in the group stage ? ~ ? and

    stage ? positive rate of positive rate of a comparison: χ2 =

    6.4803, P = 0.0109; ? ~ ? stage group the positive rate and positive rate of stage ? a comparison: χ2 = 7.9875, P =

    0.0047; ? period The positive rate of stage ? a comparison

    group: χ2 = 0.0458, P = 0.83052.2LMP1 three years after radiotherapy without recurrence of the case group than in the positive rate of recurrent cases within three years after

    radiotherapy group, in comparison with there are statistically significant. survivin in the three years after radiotherapy without recurrence of the cases positive rate of less than three years after radiotherapy for recurrence of the disease

    group, in comparison with statistical significance, Table 2. Table 2LMP1, survivin expression and recurrence after radiotherapy for three years whether the relationship between

    the Note: LMP1 three years after the radiotherapy group and no recurrence after radiotherapy positive rate and positive rate of recurrence within three years of comparison: χ2 = 5.3989,

    P = 0.0201. survivin in the radiotherapy group and no recurrence three years after the positive rate of recurrence within three years after the radiotherapy group comparison of positive rates: χ2 = 7.4532, P = 0.0063. 2.3LMP1 with

    survivin expression in nasopharyngeal carcinoma in the relationship between the Table 3 the two between factors statistically significant correlation. Expression and survivin

    expression in Table 3LMP1 Note: LMP1 and Survivin correlation between the two factors: r = 0.4960, P = 0.0000

     3 Discussion

     Apoptosis in cancer research has always been a hot issue, its occurrence in tumor development, treatment, etc. have

    played an important role. LMP1 is the EB virus latent infection is an important transformation of the expression of membrane proteins, was identified as having cancer gene functions of proteins. Kawanish [2], Komano [3], Souza [4] and other study found that LMP1 can inhibit H1299 epithelium, B cells, Burkitt's lymphoma cells and apoptosis in Jurkat cells and so on. survivin was found in a 1997 apoptosis inhibitor, belongs to a family of apoptosis inhibitory protein (IAPs), because in the embryonic tissues and most tumors showed high expression, while the normal tissues and cancer tissues did not express, so attention [5,6]. Reposted elsewhere in the paper for free download http://

     LMP1 expression and clinical stage of the relationship between the rarely reported in this set of experiments in Table 1 shows the different stages group shows no significant difference in expression of LMP1 is no obvious link with the staging of nasopharyngeal carcinoma. survivin expression in stage ? ~ ? group and the group stage ?, ? stage group

    there were significant differences in sex, ? stage group, ?

    period in the group expression was significantly higher than that in group of stage ? ~ ?, ? Stage ? phase group and

    between the two groups without significant differences in sex,

    and Qi Wei Wei [7] and others reported survivin in stage ? ~

    ? NPC tissues positive rate of 33%, ? ~ ? period 79.2% were

    similar, indicating the survivin with nasopharyngeal carcinoma is closely related to clinical staging. Radiation treatment of

    tumors is mainly through direct physical effects (necrosis) and induce gene expression in cells (apoptosis) to promote tumor cell death, in which tumors induce tumor cell apoptosis is an important mechanism in radiation therapy [8]. Activation of Caspase 3 is a terminal effector of apoptosis, once activated, the cells enter the irreversible stage of apoptosis. Radiation-activated apoptosis of tumor cells NFκB

    antagonist may be related to c IAP2 expression and

    activation of C rel [9,10]. Fa-Qing Tang et al [11] with

    the experimental verification of the LMP1 could activate NFκB

    involved in nasopharyngeal carcinoma cells, radiation therapy-

    induced apoptosis antagonist. Table 2 shows that this group LMP1 expression and recurrence within three years after radiotherapy the prognosis is closely related to, LMP1 expression of who may be prompted to poor prognosis. This is evident from clinical validation of the Fa-Qing Tang et al

    [11] were the possibility of experimental results. survivin can directly act on Caspase, the main inhibiting Caspase 3,

    Caspase 7 activity, blocking the apoptosis process can also be indirect through p21 inhibition Caspase, to prevent

    apoptosis [12], Asanuma et al [13] using quantitative RT

    PCR detection of survivin mRNA expression of survivin expression was found in inverse proportion to the sensitivity of radiation therapy, survivin expression inhibits radiation-

    induced Caspase Activation; inhibiting expression of survivin mRNA can increase the sensitivity of radiation therapy. Table 2 shows that this group survivin expression and recurrence within three years after radiation therapy is closely related to clinical cases of analysis results with previous experimental results, survivin expression was prompted to radiotherapy is ineffective, poor prognosis. The LMP1, survivin if there is both relevant link? Access to the domestic related literature, there are hair-Qing Tang et al

    [14] proposed EB virus LMP1 through activation of NFκB, AP1

    increase survivin expression. With the NFκB inhibitor IκB

    dominant negative mutants and AP 1 (c Jun) dominant

    negative mutants inhibit NFκB and AP1 activation,

    respectively, can be blocked by LMP1 increases survivin expression. Table 3 shows, LMP1 and survivin, statistically significant correlation to the clinical analysis of cases verified by two related factors.

     Through this analysis, we have reason to believe that,

    LMP1, survivin these two factors can be used as prognostic

    indicators for nasopharyngeal carcinoma, suggesting that LMP1, survivin as a cancer treatment may be molecular targets for improving therapy of tumors in experimental radiation exposure basis, to become a new cancer treatment breakthrough.

     References

     [1] Yun-Fei Xia, Qian Jian Yang, Zhang Sisi, et al. Practical radiotherapy of nasopharyngeal carcinoma study [M]. Beijing: Peking University Press, 2003.79.

     [2] Kawanish M. Expression of Epstein barr virus latent

    membrane protein 1 protects Jurkat T cells from apoptosis induced by serum deprivation [J]. Virology, 1997,228 (2): 244

     250.

     [3] Komano J, Sugiura M, Takada K. Epstein Barr virus

    contributes to the malignant phenotype and to apoptosis

    resistance in Burkitt's lymphoma cell line Akata [J]. J Virol, 1998, 72 (11): 9150 9156.

     [4] D'souza B, Rowe M, Walls D. The bfl 1 gene is

    transcriptionally upregulated by the Epstein Barr virus

    LMP1, and its expression promotes the survival of a Burkitt's

    lymphoma cell line [J]. J Virol, 2000 , 74 (14): 6652 6658.

     [5] Ambrosini G, Adida C, Altieri DC.A novel anti

    apoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997,3 (8): 917 921.

     [6] Adida C, Crotty PL, Mc Grath J, et al.Developmentally regulated expression of the novel cancer anti apoptosis

    gene survivin in human and mouse differentiation [J]. Am J Pathol, 1998,152 (1): 43 49.

     [7] Qi Wei Wei, Guo-Qing Hu. Survivin protein in

    nasopharyngeal carcinoma and its clinical significance [J]. Zhonghua ENT Journal, 2004,39 (12): 759 760.

     [8] Mi Fushun. Cell survival curve [A]. See: Guxizi, Yin Wei Bo, Liu Tae Bok, et al. Radiation Therapy [M]. Beijing: China Union Medical College, Beijing Medical University Joint

    Publishing House, 1993.232 237 .

     [9] Gunawardena K, Murray DK, Swope RE, et al.Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human

    prostate cancer cells [J]. Cancer Detect Prev, 2002,26 (3 ): 229 237.

     [10] Foo SY, Nolan GP.NF kappa B to the rescue: RELs,

    apoptosis and cellular transformation [J]. Trends Genet, 1999,15 (6): 229 235.

     [11] Tang Fa-Qing, Tang Min, GU Huan-hua, et al. LMP1 induced

    by survivin suppression 60Co apoptosis in nasopharyngeal carcinoma cells [J]. Chinese Journal of Radiation Oncology, 2003,12 (2): 120 124.

     [12] Suzuki A, Ito T, Kawano H, Hayashida M, et al.survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas mediated cell death

    [J]. Oncogene, 2000,19 ( 10): 1346 1353.

     [13] Asanuma K, Moriai R, Yajima T, et al.survivin as a radioresistance factor in pancreatic cancer [J]. Jpn J Cancer

    Res, 2000,91 (11): 1204 1209.

     [14] Tang F, Tang T, Cao Y, et al.Epstein barr virus LMP1 triggers the expression of inhibitor of opoptosis protein surviving via NF κB and AP 1 signaling pathways in

    nasopharyngeal carcinoma [J]. Expt Oncol, 2003, 25 (1): 28

    32.

     Reposted elsewhere in the paper for free download http://

Report this document

For any questions or suggestions please email
cust-service@docsford.com